Entrada Therapeutics, Inc. (TRDA) — 10-Q Filings
All 10-Q filings from Entrada Therapeutics, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 7, 2026
-
Entrada's Q3 Loss Widens Amid Steep Drop in Collaboration Revenue
— Nov 6, 2025 Risk: high
Entrada Therapeutics, Inc. (TRDA) reported a net loss of $40.5 million for the three months ended September 30, 2025, compared to a net loss of $38.9 million fo -
Entrada's Losses Widen Amid Increased R&D Spend, No Revenue
— Aug 6, 2025 Risk: high
Entrada Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss -
Entrada Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Entrada Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as CycloPorters, Inc., is based in Bosto -
Entrada Therapeutics Q3 2024: $418M Assets
— Nov 5, 2024 Risk: medium
Entrada Therapeutics, Inc. filed its quarterly report for the period ending September 30, 2024. The company reported total assets of $418 million as of Septembe -
Entrada Therapeutics Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Entrada Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o -
Entrada Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 7, 2024 Risk: low
Entrada Therapeutics, Inc. (TRDA) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Entrada Therapeutics, Inc. filed its quarterly report (10-Q) for
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX